Browse Category: Medical > Therapeutics

Categories

[Search within category]

Update To Degradable Trehalose Glycopolymers

UCLA researchers in the Department of Chemistry & Biochemistry have designed an improved version of trehalose-based glycopolymer as a degradable alternative to PEG for the purpose of stabilizing a protein during storage and transport.

PAC1 Receptor Agonists for Treatment of Obesity, Diabetes, and Fatty Liver Disease

UCLA researchers have developed novel PAC1 receptor agonists (MAXCAPs) that specifically bind and activate PAC1 receptors to induce satiety and treat multiple metabolic diseases.

Intracellular-Ligand-Responsive Cytotoxic Molecules For Selective T-Cell Mediated Cell Killing

UCLA researchers in the Department of Chemical and Biomolecular Engineering have developed a novel immunotherapeutic strategy that uses a selectively-activated cytotoxic molecule to enable tumor-specific T cell-mediated killing.

Transforming Growth Factor-Beta (TGF-β)-Responsive Single-Chain Variable Fragments And Chimeric Antigen Receptors

UCLA researchers in the Department of Chemical and Biomolecular Engineering have developed chimeric antigen receptors that are responsive to human and mouse TGF-β (Transforming Growth Factor-Beta).

Small Molecule Inhibitors of Cardiovascular and Renal Ectopic Calcification

UCLA researchers in the Department of Medicine have discovered that administration of small molecule inhibitors of ENPP1 or functional antagonists of PPi can substantially attenuate ectopic calcification. This suggests that ENPP1 and PPi can be potential pharmacological targets when developing therapeutics for pathological ectopic calcification.

Methods For The Identification And Targeting Of Brain Regions And Structures

A UCLA physician has developed a method to identify regions of the brain using Diffusion Tensor Imaging MRI to locate afferent and efferent neural tracts that lead to and from the specific region of interest. This technique will improve the accuracy and safety of brain treatments, such as electrical brain stimulation and ultrasound imaging.

Apoe4-Targeted Theraputics That Increase Sirt1

UCLA researchers have identified Alaproclate (A03) as a promising drug candidate to treat Mild Cognition Impairment (MCI) and Alzheimer’s disease (AD) through inhibition of the ApoE4 neurotoxicity.

Combination Of Approved Alzheimer's Drugs With Metabolic Enhancement For Neurodegeneration (MEND) To Comprise A Therapeutic System

UCLA researchers in the Department of Neurology have developed a novel therapeutic program for Alzheimer’s disease, based on the combination of existing AD drugs and a program to enhance metabolic activity.

Polycytotoxic T Cells

UCLA researchers in the Department of Dermatology have characterized a novel subset of CD8+ T cells, termed polycytotoxic, that mediate killing of intracellular pathogens.

DEPTOR Inhibitors

Researchers at UCLA have found a small molecule that prevents the binding of DEPTOR to mTOR. The inhibition of interaction between DEPTOR and mTOR results in selective death of multiple myeloma cells, and can therefore be used as a targeted therapy for the disease.

Inhibition Of Protein Tyrosine Phosphatase - Sigma For Hematopoietic Regeneration

UCLA Researchers have identified a novel pharmacological target for hematopoietic stem cell regeneration. They have developed small molecule inhibitors against the target and shown that the inhibitors cause rapid stem cell regeneration.

The Use of Acoustic Mechanogenetics for Immunotherapy of Solid Tumors

New modalities for treatment of certain cancers has rapidly evolved in the last few years, specifically harnessing the immune system to directly target tumor cells. The basis of the work is to engineer the patient’s own T cells to create an enhanced anticancer activity targeted to a specific marker on the tumor cell. This is accomplished by harvesting peripheral blood mononuclear cells from the patient to produce a chimeric antigen T receptor (CAR-T) which recognizes a tumor marker, expanding them to reach a therapeutic number of cells and infusing them back into the patient. While this has worked very well in treating a number of cancers, particularly B-cell malignancies, it is only in a state of infancy for treatment of solid tumors.

Patient Initiated Controlled Analgesic Remote Dispenser (PICARD)

Misuse, abuse, and diversion of prescription drugs are a major health problem in the United States, where opioid overdose caused more deaths than suicide and car accidents combined in 2013. The inventors at UCI have developed the Patient Initiated Controlled Analgesic Remote Dispenser (PICARD) system that increases patient adherence to prescribed drug protocols by requiring authentication (such as a fingerprint), dispensing single pills, and recording each event.

Nanotherapeutic For Treating Infections Caused By Intracellular And Extracellular Pathogens Ii

UCLA researchers in the Department of Chemistry and Biochemistry and Department of Medicine at the David Geffen School of Medicine have developed a new nanotherapeutic for the treatment of intracellular and extracellular pathogens.

Alpha1–2-Fucosyltransferase for Enzymatic Synthesis of Alpha1–2-linked Fucosylated Glycans

Researchers at the University of California, Davis have discovered an alpha1–2-fucosyltransferase that efficiently catalyzes the synthesis of alpha1–2-linked fucosylated glycans that can contain different internal glycans.

A Novel ER Beta Ligand Prodrug to Treat MS and Other Neurodegenerative Diseases

Researchers from the Department of Neurology and the Department of Chemistry and Biochemistry at UCLA have developed a novel ERβ ligand prodrug that is structurally designed to more easily cross the blood-brain barrier for treatment of multiple sclerosis.

Inhibitors Of The N-Terminal Domain Of The Androgen Receptor

UCLA researchers under the guidance of Drs. Matthew Rettig and Mike Jung have developed a novel family of therapeutics for use against castration resistant prostate cancer. These drugs have been shown to inhibit the androgen receptor and are unaffected by the most common drug-resistant mutations found in prostate cancer patients.

A Novel Method to Generate Specific and Permanent Macromolecular Covalent Inhibitors

UCSF researchers have invented a novel method to generate covalent macromolecular inhibitors. This strategy allows a peptide inhibitor to bind to its target protein specifically and irreversibly through proximity-enabled bioreactivity.

Therapeutic Vaccine for Chronic Hepatitis B (CHB)

Researchers at the University of California, Davis have developed a therapeutic vaccine capsule against Chronic hepatitis B.

Treatment for Retinal Disease

Researchers at the University of California, Davis have developed a method for exosome treatment of retinal disease.

Use of mutant Kv7.2 channels for anti-epileptic and pain therapies

During seizures or pain-induced inflammation, excess chemical mediators suppress potassium channels mediating neuronal activity and thereby inactivate new generation anti-epileptic drugs and painkillers acting on those channels. The invention describes a gene therapy using a genetically-engineered potassium channel that reduces adverse effects by silencing neuronal hyperactivity while maintaining normal neuronal activity in the presence of chemical mediators to treat epilepsy and pain.

Protein Kinase C Epsilon Small Molecule Inhibitors to Treat Pain, Anxiety, Alcoholism, and Nicotine Addiction

This invention provides new inhibitors to protein kinase C epsilon (PKCε) for the treatment and prophylaxis of various diseases such as pain, anxiety, alcoholism, inflammation, cancer, diabetes, and other conditions.

Engineering the protein corona of a synthetic polymer nanoparticle for broad-spectrum sequestration and neutralization of venomous biomacromolecules

Antivenoms are created by harvesting antibodies from surrogate animals that are exposed to small amounts of specific venom. This process is very costly and sometimes ineffective due to variations even within a single species. The inventors at UCI have developed a broad spectrum antivenom using nanoparticles which absorb and sequester key proteins in the venom.

Antisense Oligonucleotides and Drug Conjugates for Obesity and Diabetes Treatment

The obesity epidemic is an ongoing issue leading to significant economic and social burden, in part due to its role in the development of diabetes. Only three DFA-approved drugs for obesity treatment currently exist, none of which are without significant side effects and risks. Researchers at UCI have developed a DNA-based approach that activates metabolism, to target genes only in the fat and liver, causing increased energy expenditure and weight loss without affecting other organs. These present a viable approach to obesity treatment with minimal side effects in comparison to current drug treatments.

An Antibody to Phospho T3 of Human Huntingtin

Huntington’s disease (HD) is a neurodegenerative genetic disorder caused by abnormal function of mutated Huntingtin protein. The invention uncovers an antibody to a new post-translational modification site that affects human Huntingtin aggregation and pathogenesis of HD.

  • Go to Page: